Research Paper Volume 15, Issue 21 pp 11891—11917

Comprehensive analysis reveals XCL2 as a cancer prognosis and immune infiltration-related biomarker

class="figure-viewer-img"

Figure 8. Pan-cancer samples and the associated para-cancerous tissues were stained using multiplex immunofluorescence. The typical picture of the staining for DAPI, CD68, iNOS, and XCL2 in pan-cancer samples is shown in (A). Red, green, and pink represent CD68-, iNOS-, and XCL2-positive cells, respectively. Blue denotes the DAPI-stained nucleus. (B) Bladder urothelial carcinoma (BLCA), (C) invasive breast carcinoma (BRCA), (D) cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), (E) glioblastoma multiforme (GBM), (F) head and neck squamous cell carcinoma (HNSC), (G) kidney renal clear cell carcinoma (KIRC), (H) stomach adenocarcinoma (STAD), (I) lung adenocarcinoma (LUAD), and (J) Prostate adenocarcinoma (PRAD). XCL2 and iNOS double-positive cells with 100× and 400× amplification are shown by the note.